You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 39 No. 6, June 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Neuroleptics and Depression

Borje Wistedt, MD
Department of Psychiatry Karolinska Institute Huddinge University Hospital S-141 86 Huddinge Sweden

Arch Gen Psychiatry. 1982;39(6):745.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The risk of depressive symptoms during treatment with neuroleptics has been discussed but few controlled studies exist. There are also different types of depressive phenomena occurring in schizophrenic illness,1 but systematic observations based on controlled patient populations are needed. Knights and Hirsch recently published a study comparing schizophrenic patients treated with neuroleptic drugs with those who were not.2 It was obvious from their findings that depressive symptoms occurred considerably more often during placebo treatment than during neuroleptic therapy. I studied the effects of withdrawal from long-acting neuroleptic treatment in schizophrenic outpatients. Patients, methods, and other results have been described in detail in a previous report.3 In this study, 41 schizophrenic outpatients agreed to take part in a double-blind randomized investigation comparing the use of a placebo with the continued use of long-acting neuroleptics (fluphenazine decanoate or flupentixol decanoate). For the nonrelapsers in the placebo group and in the . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.